Scientist at Ichor in LaFayette, NY

Ichor Unveils Orally Bioavailable Antibody-like Scaffold in ACS Biochemistry

Posted Posted in Antoxerene, Ichor, RecombiPure

A landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.

Ichor CEO Delivers Keynote at TriBeta Northeast Conference

Posted Posted in Ichor

The State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration program.

Ichor to Present Double Feature at Undoing Aging Conference in Berlin

Posted Posted in Antoxerene, Ichor, Lysoclear

The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.

Ichor Nabs $600,000 Program Investment and New Partnerships in Wake of Company Expansion and Promising Early Results

Posted Posted in Ichor, Lysoclear

Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many as 15 million Americans and millions more globally. AMD has a significant impact on an individual’s quality of life through decreased independence and increased fall risk as well as the psychological and financial burden that vision loss can cause.